Introduction
============

Neuroblastoma (NB) is the most common extracranial solid malignancy in pediatric population, and accounts for approximately 15% of all childhood cancer deaths [@B1]. Despite advances in molecular mechanisms and multimodal therapy [@B2], [@B3], the clinical course of high-risk NB cases still remains unfavorable, and is featured by rapid progression and high mortality [@B1]. As a hallmark of metabolic reprogramming, even in the presence of oxygen, tumor cells uptake and convert a large amount of glucose into lactic acid to support their tumorigenecity and aggressiveness, which is known as aerobic glycolysis or Warburg effect [@B4]-[@B7]. High rates of glycolysis are consistently observed in most of tumors, accompanied by up-regulation of glycolytic enzymes such as hexokinase 2 (*HK2*), phosphoglycerate kinase 1 (*PGK1*), and enolase 1 (*ENO1*) [@B8], [@B9]. Meanwhile, small organic molecules, such as 3-bromopyruvate or 2-deoxyglucose (2-DG), are able to inhibit aerobic glycolysis and exhibit therapeutic potential for repressing tumor progression [@B10], [@B11]. Thus, it is important to investigate the mechanisms and therapeutic strategies for aerobic glycolysis during tumor progression.

Recent studies show that aerobic glycolysis is driven by activation of oncogenes or inactivation of tumor suppressors. For example, hypoxia inducible factor 1 alpha, a key mediator of hypoxic response, contributes to aerobic glycolysis by up-regulating glucose transporters 1 (*GLUT1*) and lactate dehydrogenase A (*LDHA*) [@B12]. Onocgenic c-Myc facilitates glycolysis process through inducing *HK2* and*LDHA* expression [@B13], [@B14]. Meanwhile, p53 represses aerobic glycolysis through reducing promoter activity of *GLUT1* and *GLUT4* [@B15]. Long noncoding RNA *LINC01554* inhibits aerobic glycolysis via promoting degradation of pyruvate kinase isozyme M2 (PKM2) in hepatocellular carcinoma cells [@B7]. However, the mechanisms regulating the expression of glycolytic genes in NB still remain to be determined.

In this study, through an integrative screening approach, we identify myeloid zinc finger 1 (*MZF1*) and its upstream open reading frame (uORF)-derived peptide (uPEP) as crucial regulators of aerobic glycolysis and NB progression. We demonstrate that *MZF1* is up-regulated in NB tissues and cells, and facilitates the aerobic glycolysis, growth, and aggressiveness of NB cells by up-regulating *HK2* and *PGK1*. Meanwhile, MZF1-uPEP interacts with Yin Yang 1 (YY1) to repress its transactivation, resulting in transcriptional inhibition of *MZF1* and downstream glycolytic genes. Pre-clinically, administration of a cell-penetrating MZF1-uPEP or lentivirus over-expressing MZF1-uPEP significantly suppresses aerobic glycolysis, tumorigenesis and aggressiveness, indicating the crucial roles of MZF1-uPEP in repressing *YY1*/*MZF1* axis during NB progression.

Methods
=======

Cell culture
------------

Human non-transformed mammary epithelial MCF 10A (CRL-10317) cells, embryonic kidney HEK293 (CRL-1573) cells, NB cell lines SH-SY5Y (CRL-2266), SK-N-AS (CRL-2137), BE(2)-C (CRL-2268), and IMR-32 (CCL-127), and cervical cancer HeLa (CCL-2) cells were purchased from American Type Culture Collection (Rockville, MD). Cell lines were authenticated by short tandem repeat profiling, and used within 6 months after resuscitation of frozen aliquots. Mycoplasma contamination was regularly examined using Lookout Mycoplasma PCR Detection Kit (Sigma, St. Louis, MO). Cells were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY) at 37°C in a humidified atmosphere of 5% CO~2~, and treated with 2-DG, insulin-like growth factor 1 (IGF1), or LY294002 as indicated (Sigma).

Real-time quantitative RT-PCR (qRT-PCR)
---------------------------------------

Total RNA was isolated with RNeasy Mini Kit (Qiagen Inc., Valencia, CA). Reverse transcription reactions were conducted with Transcriptor First Strand cDNA Synthesis Kit (Roche, Indianapolis, IN). Real-time PCR was performed with SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and primers ([Table S1](#SM0){ref-type="supplementary-material"}).

Western blot
------------

The peptide corresponding to MZF-uPEP (METRWGTDGVLMTAVIGAGSC) was synthesized, and coupled to keyhole limpet hemocyanin using chemical crosslinker glutaraldehyde. Rabbit anti-MZF1-uPEP polyclonal antibody was prepared by immunizing New Zealand rabbit with synthesized peptide, purified by persulfate, Sephadex G25 and DEAE-Sephadex G100 (ABclonal Biotechnology Co., Ltd, Wuhan, China), and validated by antigen peptide or fusion protein recognition. Tissue or cellular protein was extracted with 1× cell lysis buffer (Promega, Madison, WI). Western blot was performed as previously described [@B16]-[@B20], with antibodies for MZF1 (ab64866), HK2 (ab104836), PGK1 (ab113687), phosphorylated AKT (p-AKT, ab38449), AKT (ab8805, Abcam Inc., Cambridge, MA), YY1 (D3D4Q, Cell Signaling Technology, Inc., Danvers, MA), upstream transcription factor 2 (USF2, ab125184), GFP (ab290), Flag (ab1162), Myc (ab9106), or β-actin (ab6276, Abcam Inc.).

Luciferase reporter assay
-------------------------

The 5\'-untranslated region (5\'-UTR, 561 bp) of *MZF1* and promoters of *MZF1* (-1530/+30)*, HK2* (-1813/+424), or *PGK1* (-882/+246) were amplified from genomic DNA by PCR ([Table S2](#SM0){ref-type="supplementary-material"}) and subcloned into pGL3-Basic (Promega). Luciferase reporter for analyzing transactivation of *YY1* was established by annealing complementary oligonucleotides containing four canonical binding sites ([Table S2](#SM0){ref-type="supplementary-material"}) and inserting into pGL3-Basic (Promega). Mutation of YY1 or MZF1 binding site was performed with GeneTailorTM Site-Directed Mutagenesis System (Invitrogen, Carlsbad, CA) and PCR primers ([Table S2](#SM0){ref-type="supplementary-material"}). Dual-luciferase assay was performed according to manufacturer\'s instructions (Promega) [@B16], [@B17], [@B19], [@B20].

Chromatin immunoprecipitation (ChIP)
------------------------------------

ChIP assay was performed according to instructions of EZ-ChIP kit (Upstate Biotechnology, Temacula, CA) [@B16]-[@B18]. Real-time quantitative PCR (qPCR) was performed with SYBR Green PCR Master Mix (Applied Biosystems) and primers ([Table S1](#SM0){ref-type="supplementary-material"}).

Gene over-expression and knockdown
----------------------------------

Human *MZF1* coding sequence (CDS, 2205 bp), *MZF1* cDNA (2920 bp), *YY1* cDNA (1245 bp) and corresponding truncations were obtained from NB tissues by PCR primers ([Table S2](#SM0){ref-type="supplementary-material"}), and inserted into pcDNA3.1 (Invitrogen), pEGFP-N1, pCMV-3Tag-1C, pCMV-C-Flag, pCMV-N-MYC (Addgene, Cambridge, MA), or lentiviral expression vector CV186 (Genechem Co., Ltd, Shanghai, China), respectively. Human *HK2* and *PGK1* expression vectors were obtained from Genechem Co., Ltd. Mutation and frame-shift deletion of *GFP* or *MZF1-uORF* was prepared with GeneTailor^TM^ Site-Directed Mutagenesis System (Invitrogen) and primers ([Table S2](#SM0){ref-type="supplementary-material"}). Oligonucleotides encoding short hairpin RNAs (shRNAs) specific for *MZF1*, *HK2*, *PGK1*, *MZF1-uORF*, or *YY1* ([Table S3](#SM0){ref-type="supplementary-material"}) were subcloned into GV298 (Genechem Co., Ltd). Single guide RNAs (sgRNAs) were designed using Guide Design Resources (<http://crispr.mit.edu>) to target upstream or downstream region relative to transcription start site of *MZF1* ([Table S2](#SM0){ref-type="supplementary-material"}), and inserted into dCas9-VPR or dCas9-BFP-KRAB (Addgene), respectively. Stable cell lines were screened by administration of neomycin or puromycin (Invitrogen).

Rescue of target gene expression
--------------------------------

To restore target gene expression induced by *MZF1* or *MZF1-uORF*, tumor cells were transfected with shRNAs targeting *HK2* and *PGK1*, or *YY1* expression vector. To rescue gene expression altered by knockdown of *MZF1* or *MZF1-uORF*, *HK2* and *PGK1* expression vectors or shRNAs specific for *YY1* ([Table S3](#SM0){ref-type="supplementary-material"}) were transfected into tumor cells with Lipofectamine 3000 (Life Technologies, Inc., Gaithersburg, MD).

Lentiviral packaging
--------------------

Lentiviral vectors were co-transfected with packaging plasmids psPAX2 and pMD2G (Addgene) into HEK293T cells. Infectious lentivirus was harvested and filtered through 0.45 μm PVDF filters. Recombinant lentiviruses were concentrated 100-fold by ultracentrifugation (2 hrs at 120,000 g).

Fluorescence immunocytochemical staining
----------------------------------------

Tumor cells were plated on coverslips and incubated with antibodies specific for YY1 (ab109237, Abcam Inc., 1:300 dilution) or MZF1-uPEP (1:200 dilution). Then, cells were incubated with Alexa Fluor 594 goat anti-rabbit IgG or Alexa Fluor 488 goat anti-rabbit IgG (1:1000 dilutions), and stained with 4\',6-diamidino-2-phenylindole (DAPI, 300 nmol/L).

Co-immunoprecipitation (co-IP) and mass spectrometry
----------------------------------------------------

Co-IP was performed as previously described [@B17], [@B18], [@B20], with antibodies for Flag (ab1162) or Myc (ab9106, Abcam, Inc.). Bead-bound proteins were released, separated using SDS-PAGE, and analyzed by Coomassie blue staining, western blot, or mass spectrometry (Wuhan Institute of Biotechnology, Wuhan, China).

Design and synthesis of cell-penetrating peptides
-------------------------------------------------

Cell-penetrating peptide of MZF1-uPEP was designed and synthesized (ChinaPeptides Co. Ltd, Shanghai, China). The 11-amino acid long peptide (YGRKKRRQRRR) from Tat protein transduction domain served as a cell-penetrating peptide. Thus, inhibitory peptides were chemically synthesized by linking with biotin-labeled cell-penetrating peptide at N-terminus and conjugating with fluorescein isothiocyanate (FITC) at C-terminus, with purity larger than 95%.

Biotin-labeled peptide pull-down assay
--------------------------------------

Cellular proteins were isolated using 1× cell lysis buffer (Promega), and incubated with biotin-labeled peptide at 4°C overnight. Then, incubation of cell lysates with streptavidin-agarose was undertaken at 4°C for 2 hrs. Beads were extensively washed, and proteins pulled down were measured by western blot assay.

Aerobic glycolysis and seahorse extracellular flux assays
---------------------------------------------------------

Cellular glucose uptake, lactate production, and adenosine triphosphate (ATP) levels were detected as previously described [@B21]. Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were measured under basal conditions and in response to glucose (10 mmol·L^-1^), oligomycin (2 μmol·L^-1^), and 2-DG (100 mmol·L^-1^) using a Seahorse Biosciences XFe24 Flux Analyzer (North Billerica, MA) [@B22].

Sucrose gradient sedimentation
------------------------------

Tumor cells were treated with 100 μg/ml of cycloheximide (Sigma) for 5-10 min. Cell extracts were layered on top of 15-30% (w/v) linear sucrose gradient. After centrifugation at 40,000 ×g for 2 hrs at 4°C, fractions were collected using a piston-gradient fractionator (Biocomp, Fredericton, Canada). The polysome profiles were monitored by absorbance of light with a wavelength of 260 nm (A260). The polysome-bound transcripts were extracted and detected by real-time qRT-PCR.

*In vitro* cell viability, growth, and invasion assays
------------------------------------------------------

The 2-(4,5-dimethyltriazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma) colorimetric [@B18], soft agar [@B16]-[@B20] and matrigel (BD Matrigel^TM^ Matrix, BD Biosciences, Franklin Lakes, NJ) invasion [@B16]-[@B20], [@B23] assays for measuring the viability, growth, and invasion capability of tumor cells were conducted as previously described.

*In vivo* tumorigenesis and aggressiveness assays
-------------------------------------------------

All animal experiments were carried out in accordance with NIH Guidelines for the Care and Use of Laboratory Animals, and approved by the Animal Care Committee of Tongji Medical College (approval number: Y20080290). *In vivo* tumor growth (1×10^6^ tumor cells per mouse) and experimental metastasis (0.4×10^6^ tumor cells per mouse) studies were performed with blindly randomized four-week-old female BALB/c nude mice as previously described [@B16]-[@B20]. For *in vivo* therapeutic studies, tumor cells (1×10^6^ or 0.4×10^6^) were injected into dorsal flanks or tail vein of nude mice, respectively. One week later, mice were blindly randomized and treated by tail vein injection of synthesized cell-penetrating peptide (ChinaPeptides, Shanghai, China) or lentivirus-mediated *MZF1-uORF* (1×10^7^ plaque-forming units in 100 μl phosphate buffer saline). Animals were imaged using the In-Vivo Xtreme II small animal imaging system (Bruker Corporation, Billerica, MA).

Patient tissue samples
----------------------

The Institutional Review Board of Tongji Medical College approved the human tissue study (approval number: 2011-S085). All procedures were undertaken in accordance with guidelines set forth by Declaration of Helsinki. Written informed consent was obtained from all legal guardians of patients. Patients with a history of preoperative chemotherapy or radiotherapy were excluded. Human normal dorsal root ganglia tissues were collected from therapeutic abortion. Fresh specimens were collected at surgery, validated by pathological diagnosis, and stored at -80°C.

Immunohistochemistry
--------------------

Immunohistochemical staining was performed as previously described [@B16]-[@B18], with antibodies specific for Ki-67 (ab92742; 1:100 dilution), MZF1-uPEP (1:200 dilution), YY1 (ab38422; 1:200 dilution), or MZF1 (ab64866, Abcam Inc.; 1:200 dilution). The immunostaining specificity was validated by neutralizing antigen peptide incubation and IgG isotype control. The reactivity degree was assessed by at least two pathologists without knowledge of tumor groups.

Statistical analysis
--------------------

All data were shown as mean ± standard error of the mean (SEM). Cutoff values were determined by average gene expression levels. Student\'s *t* test, one-way analysis of variance (ANOVA), and χ^2^ analysis were applied to compare the difference in tumor cells or tissues. Fisher\'s exact test was applied to analyze the statistical significance of overlap between two gene lists. Pearson\'s correlation coefficient was applied for analyzing the relationship among gene expression. Log-rank test and Cox regression analysis were used to assess survival difference and hazard ratio. All statistical tests were two-sided and considered statistically significant when false discovery rate-corrected *P* values less than 0.05.

Results
=======

*MZF1* facilitates the transcription of glycolytic genes in NB
--------------------------------------------------------------

To investigate transcriptional regulators of glycolytic gene expression and tumor progression, we performed comprehensive analysis of a public dataset of 88 NB cases (GSE16476) [@B24], and identified 9, 9, and 7 glycolytic genes (*P*\<0.05) differentially expressed in NB specimens with varied status of age, death, and international neuroblastoma staging system (INSS) stages, respectively (Figure [1](#F1){ref-type="fig"}A). Based on over-lapping analysis of these results (*P*\<0.001), 7 genes were found to be consistently associated with age, death, and advanced INSS stage of NB (Figure [1](#F1){ref-type="fig"}A and [Table S4](#SM0){ref-type="supplementary-material"}). Similarly, we also found 9 transcription factors consistently associated with these clinical features of 88 NB cases (Figure [1](#F1){ref-type="fig"}A and [Table S4](#SM0){ref-type="supplementary-material"}), which were subjective to further over-lapping analysis with potential transcription factors regulating all of 7 genes revealed by Genomatix program (<http://www.genomatix.de>). The results revealed that two transcription factors, MZF1 and E2F transcription factor 3 (E2F3), might regulate expression of these glycolytic genes (Figure [1](#F1){ref-type="fig"}A). Among them, MZF1 was top transcription factor with six potential targets ([Figure S1](#SM0){ref-type="supplementary-material"}) and chosen for further study. Notably, *MZF1* was highly expressed in NB tissues with elder age (*P*=8.1×10^-5^), death (*P*=1.3×10^-6^), or advanced INSS stage (*P*=2.1×10^-4^), and was associated with poor survival of patients (*P*=6.9×10^-4^ and *P*=5.8×10^-3^, Figure [1](#F1){ref-type="fig"}B-C, and [Figure S2](#SM0){ref-type="supplementary-material"}A) as an independent prognostic factor (hazard ratio=2.330, 95% confidence interval=1.021 to 3.317, *P*=0.044). In addition, higher *MZF1* expression was observed in NB cell lines, than that in normal dorsal root ganglia ([Figure S2](#SM0){ref-type="supplementary-material"}B). To further elucidate the effects of *MZF1* on glycolytic gene expression, we chose SH-SY5Y, SK-N-AS, BE(2)-C, and IMR-32 (with low and high *MZF1* levels, respectively) cells as models. Sable over-expression or knockdown of *MZF1* increased and decreased the levels of *HK2* or *PGK1*, but not of fructose-bisphosphate C (*ALDOC*), *ENO1*, glucose-6-phosphate isomerase (*GPI*), or *LDHA*, in these NB cells, respectively (Figure [1](#F1){ref-type="fig"}D-E and [Figure S2](#SM0){ref-type="supplementary-material"}C). The MZF1 enrichment on promoters of *HK2* and *PGK1* was increased and decreased by stable over-expression or knockdown of *MZF1*, respectively (Figure [1](#F1){ref-type="fig"}F). Ectopic expression or knockdown of *MZF1* facilitated and inhibited the promoter activity of *HK2* and *PGK1* in SH-SY5Y, SK-N-AS, BE(2)-C, and IMR-32 cells, respectively, while mutation of MZF1 binding site abolished these effects (Figure [1](#F1){ref-type="fig"}G and [Figure S2](#SM0){ref-type="supplementary-material"}D). Consistently, mining of public datasets (GSE16476 and GSE62564) revealed that *HK2* (*P*=3.0×10^-10^ and*P*=2.4×10^-16^) or *PGK1* (*P*=5.3×10^-8^ and*P*=3.0×10^-23^) levels were associated with poor survival of NB patients ([Figure S2](#SM0){ref-type="supplementary-material"}E), and were positively correlated with those of *MZF1* (*R*=0.498, *P*=7.9×10^-7^; *R*=0.408, *P*=8.0×10^-5^; [Figure S2](#SM0){ref-type="supplementary-material"}F). High expression of *MZF1*, *HK2*, or *PGK1* was also associated with poor survival of patients with breast cancer, endometrial carcinoma, glioma, head and neck carcinoma, lung cancer, lymphoma, pancreatic cancer, or renal clear cell carcinoma ([Figure S3](#SM0){ref-type="supplementary-material"}). These data indicated that transcription factor MZF1 facilitated the expression of glycolytic genes in NB.

*MZF1* promotes NB progression via facilitating aerobic glycolysis
------------------------------------------------------------------

To characterize the functional roles of *MZF1* in NB cells, we applied dCas9-based clustered regularly interspaced short palindromic repeats (CRISPR) [@B25] to activate or repress expression of *MZF1*. As shown in Figure [2](#F2){ref-type="fig"}A, transfection of two independent dCas9a-MZF1 or dCas9i-MZF1 resulted in efficient over-expression or silencing of *MZF1* in NB cells, respectively. Stable transfection- or dCas9a-induced up-regulation of *MZF1* increased the ECAR, an indicator of glycolysis, in SH-SY5Y and SK-N-AS cells, while shRNA- or dCas9i-induced knockdown of *MZF1* significantly attenuated glycolytic process in BE(2)-C and IMR-32 cells (Figure [2](#F2){ref-type="fig"}B and [Figure S4](#SM0){ref-type="supplementary-material"}A). Meanwhile, OCR was reduced and enhanced in NB cells with over-expression or knockdown of *MZF1*, respectively ([Figure S4](#SM0){ref-type="supplementary-material"}B). Accordingly, ectopic expression or knockdown of *MZF1* increased and decreased the glucose uptake, lactate production, and ATP levels in NB cells, suggesting facilitated and reduced glycolysis, respectively (Figure [2](#F2){ref-type="fig"}C-D and [Figure S4](#SM0){ref-type="supplementary-material"}C-D).

To explore the roles of *HK2* and *PGK1* in *MZF1*-facilitated aerobic glycolysis, shRNAs or expression vectors of *HK2* and *PGK1* were transfected into SH-SY5Y and BE(2)-C cells to restore their expression, glucose uptake, lactate production, and ATP levels altered by stable over-expression or knockdown of *MZF1* ([Figure S5](#SM0){ref-type="supplementary-material"}A-B). In soft agar and matrigel invasion assays, the anchorage-independent growth and invasion of SH-SY5Y and BE(2)-C cells were enhanced and reduced by stable ectopic expression or knockdown of *MZF1*, which was partially rescued by silencing or over-expression of *HK2* and *PGK1*, respectively ([Figure S6](#SM0){ref-type="supplementary-material"}A-B). In addition, treatment with glycolysis inhibitor (2-DG) [@B26] abolished the increase in glucose uptake, lactate production, ATP levels, growth and invasion of NB cells induced by stable *MZF1* over-expression ([Figure S5](#SM0){ref-type="supplementary-material"}B and [Figure S6](#SM0){ref-type="supplementary-material"}A-B). *In vivo* experiments using xenograft models revealed that stable over-expression of *MZF1* promoted the tumorigenecity of SH-SY5Y cells, as displayed by increase in tumor growth, tumor weight, Ki-67 proliferative index, and elevated levels of *HK2* and *PGK1* ([Figure S7](#SM0){ref-type="supplementary-material"}A). In contrast, stable silencing of *MZF1* into BE(2)-C cells decreased the growth, weight, Ki-67 proliferation index, and expression levels of *HK2* and *PGK1* of subcutaneous xenograft tumors in nude mice ([Figure S7](#SM0){ref-type="supplementary-material"}B).

In experimental metastasis assay, nude mice treated with tail vein injection of SH-SY5Y cells stably over-expressing *MZF1* presented more lung metastatic counts and lower survival possibility ([Figure S7](#SM0){ref-type="supplementary-material"}C), while stable knockdown of *MZF1* into BE(2)-C cells resulted in less lung metastatic colonies and greater survival probability in nude mice ([Figure S7](#SM0){ref-type="supplementary-material"}D). Moreover, administration of 2-DG prevented the increased tumorigenesis and aggressiveness of NB cells *in vivo* induced by stable *MZF1* over-expression ([Figure S7](#SM0){ref-type="supplementary-material"}A and [Figure S7](#SM0){ref-type="supplementary-material"}C). These results suggested that *MZF1* promoted tumor progression via facilitating aerobic glycolysis in NB.

*MZF1-uORF*-encoded peptide inhibits *MZF1* expression
------------------------------------------------------

To explore self-regulatory mechanisms underlying *MZF1* expression, we analyzed its 5\'-UTR using ORF finder program (<https://www.ncbi.nlm.nih.gov/orffinder>), which revealed the existence of an uORF within this region (Figure [3](#F3){ref-type="fig"}A). Insertion of 5\'-UTR of *MZF1* resulted in decrease of luciferase activity, while 5\'-UTR along with *MZF1* promoter fragment facilitated the activity of luciferase reporter (Figure [3](#F3){ref-type="fig"}A). In addition, initiation codon mutation or frame-shift deletion of *uORF* within 5\'-UTR led to significant increase in luciferase activity (Figure [3](#F3){ref-type="fig"}A). Transfection of *MZF1 CDS*, but not *MZF1 cDNA* containing 5\'-UTR, resulted in increased protein and transcript levels of *MZF1* in SH-SY5Y cells (Figure [3](#F3){ref-type="fig"}B and [Figure S8](#SM0){ref-type="supplementary-material"}A). Initiation codon mutation or frame-shift deletion of *uORF* resulted in increase of *MZF1* levels in NB cells transfected by *MZF1 cDNA* containing 5\'-UTR, while over-expression or knockdown of *uORF* led to decrease and increase in transcript and protein levels of *MZF1*, respectively (Figure [3](#F3){ref-type="fig"}B and [Figure S8](#SM0){ref-type="supplementary-material"}A-B). Further mining of SmPort [@B27] and GWIPS-viz [@B28] databases implicated that this ribosome-binding *uORF* might encode a 21-amino acid peptide with high conservation in primates (Figure [3](#F3){ref-type="fig"}C). Western blot assay using anti-GFP antibody indicated the fusion expression of uPEP with GFP in HEK293 cells, which was abolished by initiation codon mutation or frame-shift deletion of *uORF* (Figure [3](#F3){ref-type="fig"}D). The translation of uPEP-GFP protein in BE(2)-C cells was also validated by Coomassie blue staining and western blot using a rabbit polyclonal antibody against uPEP (Figure [3](#F3){ref-type="fig"}E and [Figure S8](#SM0){ref-type="supplementary-material"}C) and mutation of Kozak motif locating at upstream of GFP (Figure [3](#F3){ref-type="fig"}F). Ectopic expression of GFP-tagged or Flag-tagged uPEP resulted in obvious decrease of MZF1 levels (Figure [3](#F3){ref-type="fig"}F). Notably, in response to IGF1 stimulation, the distribution of *uORF* within heavy polysomes (within fractions 10-12) was decreased, while *MZF1* antisense RNA 1 (*MZF1-AS1*), a noncoding transcript containing complementary sequence of *uORF*, was not enriched in heavy polysomes ([Figure S8](#SM0){ref-type="supplementary-material"}D). Moreover, treatment with established glycolysis activator IGF1 [@B29] led to phosphorylation of AKT, down-regulation of MZF1-uPEP, and up-regulation of MZF1 in BE(2)-C cells, which was abolished by phosphatidylinositol 3 kinase inhibitor LY294002 ([Figure S8](#SM0){ref-type="supplementary-material"}E). These data suggested that *MZF1-uORF*-encoded peptide inhibited *MZF1* expression at transcriptional level in NB cells.

MZF1-uPEP interacts with YY1 to suppress its transactivation
------------------------------------------------------------

To elucidate the mechanisms underlying MZF1-uPEP-inhibited *MZF1* expression, we first observed its subcellular localization. As shown in Figure [4](#F4){ref-type="fig"}A-B, GST-tagged or Flag-tagged MZF1-uPEP was mainly expressed within the nuclei of HeLa and BE(2)-C cells. Immunofluorescence assay using MZF1-uPEP specific antibody also revealed the nuclear or cytoplasmic enrichment of MZF1-uPEP in BE(2)-C cells, which was enhanced by transfection of *MZF1-uORF* (Figure [4](#F4){ref-type="fig"}C). Treatment with leptomycin B (LMB), an established nuclear export inhibitor [@B30], resulted in obvious aggregation of MZF1-uPEP within the nucleus of SH-SY5Y cells (Figure [4](#F4){ref-type="fig"}C). Then, to identify the protein partner of MZF1-uPEP, we performed the co-IP followed by a proteomic analysis of pulled down proteins in BE(2)-C cells. Mass spectrometry revealed 1321 differential proteins between empty vector (mock) and *MZF1-uORF* transfection groups ([Table S5](#SM0){ref-type="supplementary-material"}), and two of them (Figure [4](#F4){ref-type="fig"}D) were potential transcription factors regulating *MZF1* expression revealed by UCSC Genome Browser ([Table S6](#SM0){ref-type="supplementary-material"}). Further validating co-IP and western blot assays indicated that YY1 protein, but not USF2, was able to interact with MZF1-uPEP in BE(2)-C cells, which was abolished by IGF1 treatment (Figure [4](#F4){ref-type="fig"}E and [Figure S8](#SM0){ref-type="supplementary-material"}F). Co-localization of MZF1-uPEP and YY1 was observed in the nucleus of NB cells (Figure [4](#F4){ref-type="fig"}F). Deletion-mapping experiments indicated that zinc finger (ZNF) domain of YY1 (amino acids 258-414) was required for its binding to MZF1-uPEP (Figure [4](#F4){ref-type="fig"}G). Notably, the expression of YY1 and its interaction with MZF1-uPEP were higher in NB cell lines, than that in normal dorsal root ganglia ([Figure S8](#SM0){ref-type="supplementary-material"}G). Importantly, stable over-expression or knockdown of *MZF1-uORF* resulted in decreased and increased transactivation of YY1, which was prevented by ectopic expression or silencing of *YY1* in BE(2)-C and SH-SY5Y cells, respectively (Figure [4](#F4){ref-type="fig"}H).

In addition, transfection of *YY1* into BE(2)-C cells led to increase in *MZF1* promoter activity, while mutation of YY1 binding site or stable transfection of *MZF1-uORF* abolished these effects ([Figure S8](#SM0){ref-type="supplementary-material"}H). Ectopic expression or knockdown of *MZF1-uORF* decreased and increased the binding of YY1*to MZF1* promoter in NB cells, which was abolished by stable over-expression or knockdown of *YY1*, respectively (Figure [4](#F4){ref-type="fig"}I). Collectively, these results indicated that MZF1-uPEP interacted with YY1 to suppress its transactivation in NB cells.

MZF1-uPEP exerts tumor suppressive roles by repressing YY1
----------------------------------------------------------

To further investigate the functional roles of MZF1-uPEP, we performed rescue studies in NB cells. Stable ectopic expression of *MZF1-uORF* prevented the increase in glucose uptake, lactate production, ATP levels, growth, invasion, and metastasis of NB cells *in vitro* and *in vivo* induced by IGF1 stimulation ([Figure S9](#SM0){ref-type="supplementary-material"}A-D). Stable transfection of *MZF1-uORF* or sh-uORF \#1 led to significantly decreased and increased expression of*MZF1* and downstream genes (*HK2* and *PGK1*) in BE(2)-C and SH-SY5Y cells ([Figure S10](#SM0){ref-type="supplementary-material"}A-B), which was abolished by ectopic expression or knockdown of *YY1*, respectively ([Figure S10](#SM0){ref-type="supplementary-material"}A-B). Meanwhile, ectopic expression or silencing of *YY1* abolished the decrease or increase in glucose uptake, lactate production, and ATP levels of NB cells induced by stable over-expression or knockdown of *MZF1-uORF* ([Figure S10](#SM0){ref-type="supplementary-material"}C). In MTT colorimetric, soft agar, and matrigel invasion assays, over-expression or silencing of *YY1* reversed the decrease or increase of viability, growth and invasiveness of NB cells induced by stable ectopic expression or knockdown of *MZF1-uORF*, respectively ([Figure S10](#SM0){ref-type="supplementary-material"}D-F). These data indicated that MZF1-uPEP exerted tumor suppressive roles by repressing YY1.

Therapeutic efficiency of cell-penetrating MZF1-uPEP
----------------------------------------------------

Then, we further investigated the therapeutic efficiency of cell-penetrating MZF1-uPEP on biological behaviors of NB cells. Administration of a cell-penetrating FITC-labeled MZF1-uPEP with YY1 inhibiting properties, termed as YIP-21, resulted in its obvious nuclear enrichment in BE(2)-C cells (Figure [5](#F5){ref-type="fig"}A). Biotin-labeled peptide pull-down assay revealed that YIP-21, but not control peptide (CTLP), was able to bind with YY1 (Figure [5](#F5){ref-type="fig"}B). Administration of YIP-21 led to decrease in the viability of NB cells (Figure [5](#F5){ref-type="fig"}C), but not of non-transformed MCF 10A or transformed HEK293 cells without endogenous interaction between MZF1-uPEP and YY1 (Figure [5](#F5){ref-type="fig"}D and [Figure S8](#SM0){ref-type="supplementary-material"}G). In addition, treatment with YIP-21 decreased the anchorage-independent growth and invasion of BE(2)-C cells (Figure [5](#F5){ref-type="fig"}E-F). To test *in vivo* therapeutic potency of YIP-21, tail vein administration of YIP-21 or CTLP was performed in nude mice bearing subcutaneous xenograft tumors or lung metastasis formed by BE(2)-C cells. Administration of YIP-21 resulted in decreased growth and weight of subcutaneous xenograft tumors in nude mice (Figure [5](#F5){ref-type="fig"}G). The Ki-67-positive cells, expression of *MZF1* and its downstream genes, glucose uptake, lactate production, and ATP levels within subcutaneous xenograft tumors were also significantly reduced by YIP-21 treatment (Figure [5](#F5){ref-type="fig"}G-H). In experimental metastasis assay, nude mice treated with YIP-21 presented with less lung metastatic counts and longer survival time (Figure [5](#F5){ref-type="fig"}I). Consequently, these results demonstrated that cell-penetrating MZF1-uPEP suppressed tumorigenesis and aggressiveness of NB cells.

Therapeutic efficiency of *MZF1-uORF* over-expression
-----------------------------------------------------

To further assess the therapeutic efficacy of lentivirus-mediated *MZF1-uORF* over-expression on tumor progression, nude mice were treated with subcutaneous or tail vein injection of IMR-32 cells stably expressing red fluorescent protein. One week later, mice were randomly divided into groups, and received intravenous administration of lentivirus carrying empty vector (mock) or *MZF1-uORF*. Administration of lentivirus-mediated *MZF1-uORF* dramatically reduced the growth and weight of xenograft tumors ([Figure S11](#SM0){ref-type="supplementary-material"}A), decreased the Ki-67 proliferation index ([Figure S11](#SM0){ref-type="supplementary-material"}A), increased the MZF1-uPEP levels ([Figure S11](#SM0){ref-type="supplementary-material"}B), inhibited the expression of *MZF1* and downstream glycolytic genes ([Figure S11](#SM0){ref-type="supplementary-material"}C-D), and attenuated the glucose uptake, lactate production, and ATP levels within xenograft tumors ([Figure S11](#SM0){ref-type="supplementary-material"}E). In experimental metastasis assay, nude mice treated with tail vein administration of lentivirus-mediated *MZF1-uORF* presented fewer lung metastatic counts and longer survival time ([Figure S11](#SM0){ref-type="supplementary-material"}F). These data indicated that lentivirus-mediated over-expression of*MZF1-uORF* suppressed NB progression.

MZF1-uPEP/*YY1*/*MZF1* expression is associated with NB outcome
---------------------------------------------------------------

We then analyzed the significance of MZF1-uPEP, *YY1*, *MZF1*, and target genes in NB. Immunohistochemical staining revealed that MZF1-uPEP was expressed in nuclei and cytoplasm of tumor cells (Figure [6](#F6){ref-type="fig"}A and [Figure S12](#SM0){ref-type="supplementary-material"}A), and detected in 22/42 (52.4%) NB cases, with lower expression in those with elder age (*P*=0.038), poor differentiation (*P*=0.024), higher mitosis karyorrhexis index (MKI, *P*=0.037), or advanced *INSS* stages (*P*=0.007, [Table S7](#SM0){ref-type="supplementary-material"}). In these patients, low MZF1-uPEP expression was associated with poor survival probability (*P*=3.0×10^-3^, Figure [6](#F6){ref-type="fig"}B). Meanwhile, nuclear expression of YY1 (29/42) and MZF1 (26/42) was observed in these NB cases (Figure [6](#F6){ref-type="fig"}A and [Table S8](#SM0){ref-type="supplementary-material"}). The immunostaining of MZF1-uPEP and YY1 was negatively or positively associated with MZF1 immunoreactivity in NB cases, respectively ([Table S9](#SM0){ref-type="supplementary-material"}). Higher expression of *YY1*, *MZF1*, *HK2*, or *PGK1* was observed in NB tissues, than that in normal dorsal root ganglia (Figure [6](#F6){ref-type="fig"}C-D). High *YY1* expression was associated with poor outcome of patients with NB (GSE16476 and GSE62564, *P*=2.6×10^-4^ and *P*=4.9×10^-12^), breast cancer (*P*=3.1×10^-3^), endometrial carcinoma (*P*=6.1×10^-3^), glioma (*P*=1.6×10^-11^), head and neck carcinoma (*P*=1.2×10^-2^), lung cancer (*P*=5.5×10^-3^), lymphoma (*P*=1.0×10^-3^), pancreatic cancer (*P*=1.4×10^-4^), or renal clear cell carcinoma (*P*=3.0×10^-4^, Figure [6](#F6){ref-type="fig"}B and [Figure S12](#SM0){ref-type="supplementary-material"}B-C). In 88 NB cases (GSE16476), high levels of *YY1* were noted in tissues with elder age (*P*=4.1×10^-2^), death (*P*=6.5×10^-4^), or advanced INSS stage (*P*=6.4×10^-3^, Figure [6](#F6){ref-type="fig"}E). In addition, *YY1* expression was positively correlated with that of *MZF1*, *HK2*, or *PGK1* in these NB tissues (Figure [6](#F6){ref-type="fig"}F). These results indicated that expression of MZF1-uPEP/*YY1*/*MZF1* was associated with NB outcome.

Discussion
==========

Aerobic glycolysis facilitates malignant cell transformation, tumor initiation and aggressive progression [@B5], while inhibition of glycolysis impairs growth and metastasis of many tumor cells [@B10], [@B11], indicating an efficient therapeutic approach for tumors. Recent studies show that *LDHA* and *LDHB* are dispensable for aerobic glycolysis in NB [@B31], suggesting involvement of other glycolytic genes in this process. Among them, *HK2* is mainly expressed in cancers, and phosphorylates glucose to produce glucose-6-phosphate, a rate-limiting and irreversible step of glycolysis [@B8]. In mouse models, *HK2* plays a vital role in tumor initiation and maintenance [@B32]. Elevated *HK2* is associated with poor survival of hepatocellular carcinoma, while inhibition of *HK2* expression abrogates the tumorigenesis of tumor cells [@B33]. PGK1, a rate-limiting enzyme of glycolytic pathway, catalyzes the transfer of high-energy phosphate from 1-position of 1,3-diphosphoglycerate to ADP, and is essential for ATP generation [@B34]. *PGK1* is up-regulated in breast cancer [@B35], pancreatic ductal adenocarcinoma [@B36], and hepatocellular carcinoma [@B37], while depletion of *PGK1* dramatically reduces the proliferation and metastasis of cancer cells, indicating an oncogenic role of *PGK1* in tumor progression [@B38]. In this study, we identify MZF1 as a transcription factor facilitating the expression of glycolytic genes *HK2* and *PGK1* in NB. In addition, we demonstrate that a peptide encoded by *MZF1-uORF* binds to YY1, resulting in decreased transactivation of YY1 and repressed expression of *MZF1* and downstream glycolytic genes *HK2* and *PGK1* in NB cells (Figure [6](#F6){ref-type="fig"}G), implying a negative feedback loop of uORF-encoded peptide in *MZF1* expression. Meanwhile, in response to stimulation of glycolysis activator, MZF1-uPEP is down-regulated to disrupt this negative feedback loop, resulting in enhanced MZF1 expression and aerobic glycolysis of NB cells.

*MZF1*, one member of Kruppel family proteins, is essential for the differentiation, proliferation, and migration of hematopoietic cells [@B39], [@B40]. As a bi-functional transcription factor, MZF1 contains 13 zinc finger domains, and represses or activates gene transcription via binding to promoters [@B40]. Recent studies show that *MZF1* plays an important role in tumorigenesis and aggressiveness. Forced expression of *MZF1* induces malignant transformation of NIH3T3 cells, and initiates tumor formation in athymic mice [@B41]. MZF1 is involved in the etiology of many solid tumors, such as lung cancer [@B42], breast cancer [@B43], colorectal cancer [@B44], hepatocellular carcinoma [@B45], and cervical cancer [@B46]. MZF1 facilitates the transcription of *c-MYC*, and is responsible for growth, migration, and invasion of lung adenocarcinoma cells [@B42]. In breast cancer, MZF1 activates the expression of cathepsin B to increase the invasion of cancer cells [@B43]. Over-expression of *MZF1* leads to transactivation of anexelekto (*AXL*) promoter and increase of migratory, invasive, and metastatic potential of colorectal cancer cells [@B44]. In hepatocellular carcinoma, MZF1 enhances the transcription of protein kinase C alpha (*PKCα*), thus facilitating the migration and invasion of cancer cells [@B45]. Meanwhile, MZF1 suppresses the migratory and invasive capability of cervical cancer cells by inhibiting transcription of matrix metalloproteinase-2 (*MMP-2*) [@B46]. These results indicate that *MZF1* exerts oncogenic or tumor suppressive roles via transcriptional changes associated with malignant cell migration and invasiveness in a context-dependent manner. However, the roles of MZF1 in aerobic glycolysis during tumor progression still remain elusive. In this study, *MZF1* was identified as an independent prognostic factor for poor outcome of NB patients, while *HK2* and *PGK1* were direct target genes of *MZF1*. Our gain- and loss-of-function studies indicated that *MZF1* promoted aerobic glycolysis, growth, and invasiveness of NB cells, suggesting the oncogenic roles of *MZF1* in NB progression.

The widespread presence of uORF within 5\'-UTR is one of the mechanisms regulating gene expression [@B47], [@B48]. Approximate 50% of human transcripts contain uORF [@B49], and uORF is able to repress translation of mRNAs through disturbing ribosomal scanning or altering mRNA stability [@B50]. For example, sex lethal protein binds to a *cis*-regulatory element within uORF, and imposes a negative effect on protein translation in *Drosophila* [@B51]. Recent ribosome profiling and validating studies indicate the generation of short peptides encoded by uORFs [@B47], [@B50], and some uORF-encoded peptides are important for translational regulation [@B52], [@B53]. The 5\'-UTR of CCAAT/enhancer-binding protein homologous protein (*CHOP*) contains a conserved uORF which encodes a 31-amino acid peptide that inhibits the translation of *CHOP* [@B54]. In this study, we identified a conserved uORF within *MZF1* 5\'-UTR, which encoded a small peptide that bound to YY1 protein. Notably, MZF1-uPEP inhibited YY1-facilitated transcription of *MZF1*, indicting a novel action mode of uORF-encoded peptide in regulating gene transcription rather than protein translation. In addition, tumor suppressive functions of MZF1-uPEP were mediated, at least in part, through interacting with YY1 protein in NB cells.

*YY1* is a transcription factor of GLI-Kruppel family, and plays a regulatory role in cellular growth, oncogenic transformation, epithelial-mesenchymal transition, and metastasis [@B55]. Human YY1 protein possesses a transactivation domain, a repression domain, and four C2H2-type zinc fingers [@B55], and activates or inactivates gene transcription depending on promoter contexts [@B56]. *YY1* is highly expressed in many types of cancerous tissues, including prostate cancer, colon cancer, liver cancer, and lung cancer [@B57]. In colon cancer, *YY1* promotes the growth and Wnt signaling pathway of cancer cells through inhibiting *p53* [@B58]. In addition, *YY1* facilitates the transcription of p-glycoprotein in acute lymphoblastic lekeumia, and is associated with poor survival of patients [@B59]. In this study, we found that *YY1* promoted the expression of *MZF1* in NB cells, resulting in facilitated glycolytic gene expression and tumor progression. In addition, MZF1-uPEP bound to zinc finger domain of YY1, resulting in repression of *YY1* transactivation in NB cells. Importantly, administration of a cell-penetrating MZF1-uPEP or lentivirus over-expressing MZF1-uPEP was able to suppress aerobic glycolysis, tumorigenesis, and aggressiveness of NB cells, suggesting the crucial roles of MZF1-uPEP in repressing *YY1*/*MZF1* axis in aerobic glycolysis and tumor progression.

Conclusions
===========

In summary, we demonstrate that *MZF1* is associated with poor outcome of NB, and exerts oncogenic roles in aerobic glycolysis and tumor progression. Meanwhile, *MZF1-*uORF-encoded peptide suppresses the *MZF1* expression, aerobic glycolysis, growth, and aggressiveness of NB cells. Mechanistically, *MZF1* promotes the expression of glycolytic genes *HK2* and *PGK1*, while MZF1-uPEP binds to YY1 to repress its transactivation, resulting in transcriptional suppression of *MZF1* and downstream glycolytic genes. Administration of a cell-penetrating MZF1-uPEP or lentivirus over-expressing MZF1-uPEP suppresses the aerobic glycolysis, tumorigenesis, and aggressiveness of NB cells. Since MZF1 expression is negatively regulated by microRNAs let-7e and let-7d in breast cancer cells [@B60], the roles of let-7 family members in regulating MZF1-mediated aerobic glycolysis during NB progression warrant investigation. In addition, further studies are needed to explore the potential roles of noncoding RNA *MZF1-AS1* in regulating MZF1-uPEP expression in NB. We believe that this study extends our knowledge about the regulation of aerobic glycolysis by transcription factor and its derived uPEP, and suggests that *MZF1* and *YY1* may be potential therapeutic targets for tumor progression.
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![***MZF1* facilitates the transcription of glycolytic genes in NB. (A)** Venn diagram indicating the identification of glycolytic genes (left panel) and transcription factors (right panel) differentially expressed in 88 NB cases (GSE16476) with various status of age, death, and INSS stages, and the over-lapping analysis with potential transcription factors regulating glycolytic genes revealed by Genomatix program. The middle panel showing the potential transcription factors regulating expression of glycolytic genes. **(B)** Mining of a public microarray dataset (GSE16476) revealing the *MZF1* levels in NB tissues with different status of age, death, or INSS stages. **(C)** Kaplan-Meier curve showing overall survival of 88 NB patients (GSE16476) with high or low*MZF1* expression (cutoff value=226.6). **(D** and **E)** Real-time qRT-PCR (D, normalized to β-actin, *n*=4) and western blot (E) assays indicating the transcript and protein levels of *MZF1*, *ALDOC*, *ENO1*, *GPI*, *HK2*, *LDHA*, or *PGK1* in SH-SY5Y and BE(2)-C cells stably transfected with empty vector (mock), *MZF1*, scramble shRNA (sh-Scb), or sh-MZF1.**(F)** ChIP and qPCR assays showing the binding of *MZF1* to promoters of *HK2* and *PGK1* in SH-SY5Y, SK-N-AS, BE(2)-C, and IMR-32 cells stably transfected with mock, *MZF1*, sh-Scb, or sh-MZF1 (*n*=4). **(G)** Dual-luciferase assay indicating the promoter activity of *HK2* and *PGK1* with wild-type (WT) or mutant (Mut) MZF1 binding site in SH-SY5Y and BE(2)-C cells stably transfected with mock, *MZF1*, sh-Scb, or sh-MZF1 (*n*=6). Fisher\'s exact test for over-lapping analysis in **A**. Student\'s *t* test compared the difference in**B**. Log-rank test for survival comparison in **C**. Student\'s *t* test and ANOVA compared the difference in **D**,**F** and **G**. \* *P*\<0.05, \*\* *P*\<0.01 vs. mock or sh-Scb. ^Δ^ *P*\<0.05 vs. WT. Bars are means and whiskers (min to max) in **B**. Data are shown as mean ± s.e.m. (error bars) and representative of three independent experiments in **D**-**G**.](thnov10p1555g001){#F1}

![***MZF1* promotes the aerobic glycolysis of NB cells. (A)** Western blot assay indicating the expression of MZF1, HK2, and PGK1 in SH-SY5Y, SK-N-AS, BE(2)-C, and IMR-32 cells stably transfected with dCas9a control (dCas9a-CTL), dCas9a-MZF1, dCas9i control (dCas9i-CTL), or dCas9i-MZF1. **(B)** Seahorse tracing curves (left panel) and ECAR bars (right panel) of SH-SY5Y and BE(2)-C cells stably transfected with empty vector (mock), *MZF1*, scramble shRNA (sh-Scb), sh-MZF1, dCas9a-CTL, dCas9a-MZF1, dCas9i-CTL, or dCas9i-MZF1, and those treated with glucose (10 mmol·L^-1^), oligomycin (2 μmol·L^-1^), or 2-deoxyglucose (2-DG, 100 mmol·L^-1^) at indicated (4 replicates for each point). **(C** and**D)** Glucose uptake, lactate production, and ATP levels in SH-SY5Y (C) and BE(2)-C (D) cells stably transfected with mock, *MZF1*, sh-Scb, sh-MZF1, dCas9a-CTL, dCas9a-MZF1, dCas9i-CTL, or dCas9i-MZF1 (*n*=4). Student\'s *t* test and ANOVA compared the difference in **B**-**D**. \*\* *P*\<0.01 vs. mock, sh-Scb, dCas9a-CTL, or dCas9i-CTL. Data are shown as mean ± s.e.m. (error bars) and representative of three independent experiments in **A**-**D**.](thnov10p1555g002){#F2}

![***MZF1-uORF*-encoded peptide inhibits *MZF1* expression. (A)** Dual-luciferase assay (right panel) indicating the activity of luciferase reporters containing wild-type, mutant, or deletion forms of *uORF* within 5\'-UTR and promoter fragment of *MZF1* (left panel) in SH-SY5Y and BE(2)-C cells (*n*=4). **(B)** Western blot assay showing the levels of MZF1 in SH-SY5Y cells transfected with empty vector (mock), *MZF1* coding sequence (CDS), *MZF1* containing wild-type, mutant, or deletion forms of 5\'-UTR, scramble shRNA (sh-Scb), or sh-uORF. **(C)** Mining of GWIPS-viz database (left panel) revealing the ribosome profiling at uORF region of *MZF1* (outlined), with homology of *MZF1-uORF*-encoded amino acid sequence as indicated (right panel). **(D)** Western blot assay using antibody specific for GFP (upper panel) indicating the expression of GFP and MZF1-uPEP-GFP fusion protein in HEK293 cells transfected with *GFP* or wild-type, mutation, or deletion forms of *MZF1-uORF-GFP* as indicated (lower panel). **(E)** Western blot assay using MZF1-uPEP specific antibody showing the expression of MZF1-uPEP and MZF1-uPEP-GFP fusion protein in BE(2)-C cells transfected with *GFP* or *MZF1-uORF-GFP*, with synthesized scramble (Scb) peptide or uPEP as controls. **(F)** Western blot assay (lower panel) indicating the expression of GFP, MZF1-uPEP, or MZF1 in BE(2)-C cells transfected with wild-type or mutant *GFP*, *MZF1-uORF-GFP* constructs, or Flag-tagged *MZF1-uORF* constructs as indicated (upper panel). ANOVA compared the difference in **A**. \* *P*\<0.05 vs. mock. Data are shown as mean ± s.e.m. (error bars) and representative of three independent experiments in **A**, **B**, and**D-F**.](thnov10p1555g003){#F3}

![**MZF1-uPEP interacts with YY1 to suppress its transactivation. (A** and**B)** Confocal images showing the localization of MZF1-uPEP-GFP fusion protein or Flag-tagged MZF1-uPEP in HeLa and BE(2)-C cells transfected with wild-type (WT) or mutant (Mut) *GFP*, *MZF1-uORF-GFP* constructs, or Flag-tagged *MZF1-uORF*. **(C)** Immunofluorescence assay using MZF1-uPEP specific antibody indicating the localization of MZF1-uPEP in BE(2)-C cells transfected with N-terminal Flag vector or Flag-tagged *MZF1-uORF*, and that of SH-SY5Y cells treated with DMSO or LMB (20 nmol/L) for 48 hrs. **(D)** Coomassie blue staining (left panel) and Venn diagram (right panel) showing mass spectrometry (MS)-identified differential proteins pulled down by Flag antibody from BE(2)-C cells transfected with N-terminal Flag or Flag-tagged *MZF1-uORF*, and the over-lapping analysis with potential transcription factors of *MZF1* revealed by UCSC Genome Browser. **(E)** Co-IP and western blot assays revealing the interaction of MZF1-uPEP with YY1 or USF2 in BE(2)-C cells. **(F)** Immunofluorescence staining assay showing the co-localization of MZF1-uPEP (green) and YY1 (red) in SH-SY5Y cells, with nuclei stained by DAPI (blue). Scale bar: 10 μm. **(G)** Co-IP and western blot assays (upper panel) revealing the interaction between MZF1-uPEP and YY1 in BE(2)-C cells transfected with Flag-tagged *MZF1-uORF* and full-length or truncations of Myc-tagged *YY1* as indicated (lower panel). **(H** and**I)** Dual-luciferase (H) and ChIP qPCR (I) assays showing the activity of reporter containing four canonical YY1 binding sites and binding of YY1 to *MZF1* promoter in NB cells stably transfected with mock, *MZF1-uORF*, sh-Scb, or sh-uORF, and those co-transfected with *YY1* or sh-YY1 (*n*=4). ANOVA compared the difference in **H** and **I**. \* *P*\<0.05 vs. mock or sh-Scb. Data are shown as mean ± s.e.m. (error bars) and representative of three independent experiments in **A**-**C** and**E-I**.](thnov10p1555g004){#F4}

![**Therapeutic efficiency of cell-penetrating MZF1-uPEP. (A)** Representative confocal images indicating the distribution of FITC-labeled control (CTLP) or YY1 inhibitory peptide (YIP-21, 20 μmol/L) in BE(2)-C cells, with nuclei stained by DAPI (blue). Scale bar: 10 μm. **(B)** Peptide pull-down assay showing the levels of YY1 pulled down by biotin-labeled CTLP or YIP-21 (20 μmol/L) from SH-SY5Y cells. **(C** and**D)** MTT colorimetric assay indicating the viability of BE(2)-C, MCF 10A, or HEK293 cells treated with CTLP or YIP-21 (20 μmol/L, *n*=6). **(E** and**F)** Representative images (upper panel) and quantification (lower panel) of soft agar (E) and matrigel invasion (F) assays showing the growth and invasion of BE(2)-C cells treated with CTLP or YIP-21 (20 μmol/L, *n*=4) for 48 hrs.**(G)** Representative images, *in vivo* growth curve, tumor weight, Ki-67 immunostaining, and expression of *MZF1* and downstream glycolytic genes within BE(2)-C-formed subcutaneous xenograft tumors (*n*=5 per group) in nude mice that treated with tail vein injection of CTLP or YIP-21 (3 mg·kg^-1^) as indicated. **(H)** Glucose uptake, lactate production, and ATP levels of BE(2)-C-formed subcutaneous xenograft tumors in nude mice (*n*=5 per group) that treated with tail vein injection of CTLP or YIP-21 (3 mg·kg^-1^). **(I)** Representative images (middle panels) and metastatic counts of lungs (lower left panel) and Kaplan-Meier curves (lower right panel) of nude mice (*n*=5 per group) treated with tail vein injection of BE(2)-C cells and CTLP or YIP-21 (3 mg·kg^-1^) as indicated (upper panel). Student\'s *t* test and ANOVA compared the difference in **C**-**I**. Log-rank test for survival comparison in **I**. \* *P*\<0.05, \*\* *P*\<0.01, \*\*\* *P*\<0.001 vs. CTLP. NS, non-significant. Data are shown as mean ± s.e.m. (error bars) and representative of three independent experiments in **A**-**F**.](thnov10p1555g005){#F5}

![**MZF1-uPEP/*YY1*/*MZF1* expression is associated with NB outcome. (A)** Representative images of immunohistochemical staining showing the expression patterns of MZF1-uPEP, YY1, and MZF1 in tumor cells of NB specimens (arrowheads, brown). Scale bars: 50 μm. **(B)** Kaplan-Meier curves indicating overall survival of 42 NB patients with high or low MZF1-uPEP immunostaining in 88 (GSE16476) NB cases with low or high expression levels of *YY1* (cutoff value=1003.1). **(C** and**D)** Western blot (C) and real-time qRT-PCR (D, normalized to β-actin) assays showing the expression of *YY1*,*MZF1*, and target genes in normal dorsal root ganglia (DG), NB tissues (*n*=42), and NB cell lines. **(E)** Mining of a public microarray dataset (GSE16476) revealing the levels of *YY1* in NB tissues with different status of age, death, or INSS stages. **(F)** The positive expression correlation of*YY1* with *MZF1*, *HK2*, or *PGK1* in 88 NB cases (GSE16476). **(G)** The mechanisms underlying MZF1-uPEP-suppressed tumor progression: as an uORF-encoded small peptide, MZF1-uPEP directly binds to YY1 to repress its transactivation, resulting in decreased transcription of *MZF1* and downstream target glycolytic genes, and reduced aerobic glycolysis and tumor progression. Log-rank test for survival comparison in **B**. Student\'s *t* test compared the difference in **D** and**E**. Pearson\'s correlation coefficient analysis for gene expression in **F**. \* *P*\<0.05 vs. DG. Data are shown as mean ± s.e.m. (error bars) and representative of three independent experiments in **C** and **D**. Bars are means and whiskers (min to max) in **E**.](thnov10p1555g006){#F6}
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